<img src="https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png" style="height:64px;margin-right:32px"/>

# Which mutations, if any, lead to resistance to both chemotherapy and radiotherapy? Are there specific mutations that lead to cross resistance?

Several well-characterized mutations and pathway alterations can confer resistance to both chemotherapy and radiotherapy, but there is no single universal “cross‑resistance mutation.” Most cross resistance arises from changes in DNA‑damage response, apoptosis regulation, and cell‑cycle control that blunt the effects of both genotoxic drugs and ionizing radiation.[^1][^2][^3]

## Key shared mechanisms

- Both cytotoxic chemotherapy (e.g., platinum drugs, alkylators, anthracyclines) and radiotherapy kill tumor cells mainly by inducing DNA damage, especially double‑strand breaks.[^3]
- Mutations that enhance DNA repair, disable apoptosis, or alter checkpoints can therefore protect against both modalities and lead to cross resistance.[^1][^3]


## TP53 and p53‑pathway alterations

- Loss‑of‑function *TP53* mutations are among the clearest examples associated with reduced response to both chemotherapy and radiation, because mutant p53 fails to induce cell‑cycle arrest and apoptosis after DNA damage.[^4][^5]
- Clinical data in sarcomas and other tumors show that *TP53* mutations correlate with radioresistance and poorer local control after irradiation, and numerous studies link mutant p53 to poorer responses to DNA‑damaging drugs.[^6][^5]
- Alterations that suppress p53 signaling without mutating *TP53* directly (e.g., *MDM2* amplification, *CDKN2A* loss) can similarly promote resistance, although their association with radioresponse can be weaker or context‑dependent.[^6][^4]


## DNA‑damage response and repair genes

- Upregulation or activating changes in DNA‑damage response (DDR) pathways (e.g., homologous recombination, non‑homologous end‑joining, nucleotide excision repair) can make tumor cells more efficient at repairing lesions produced by both chemotherapy and radiation.[^2][^3]
- Reviews of genetic determinants of chemo‑ and radioresistance highlight elevated expression or activity of DDR genes such as *RAD51* (HR repair), *ERCC1* (nucleotide excision repair), and DNA‑PK components as contributors to resistance to both treatments.[^7][^3][^1]
- In some settings, DDR hyperactivation is acquired under treatment pressure (for example, cisplatin‑resistant tumors with broadly increased DDR gene expression that show cross resistance to other DNA‑damaging agents).[^8][^2]


## Anti‑apoptotic and survival signaling

- Overexpression or activating changes in anti‑apoptotic proteins (e.g., BCL‑2 family members, survivin) can blunt death signaling after DNA damage, contributing to cross resistance.[^1]
- In lung adenocarcinoma models, docetaxel‑resistant cells that became cross‑resistant to radiotherapy showed increased expression of survivin and RAD51, driven by c‑MYC, and downregulation of miR‑451; restoring miR‑451 resensitized them to radiation.[^9]
- Activation of pro‑survival pathways such as NF‑κB, PI3K–AKT, and others is frequently implicated in resistance to both chemo‑ and radiotherapy in multiple tumor types.[^10][^1]


## Examples of documented cross resistance

- In nasopharyngeal carcinoma, cells surviving radiotherapy display increased radioresistance and cross resistance to paclitaxel and cisplatin, linked to enhanced survival and repair mechanisms rather than a single recurrent gene mutation.[^10]
- In lung adenocarcinoma, the miR‑451–c‑MYC–survivin/RAD51 axis is a defined molecular route by which acquired chemoresistance (to docetaxel) leads to acquired radioresistance.[^9]
- Reviews of cross resistance highlight that prolonged exposure to one genotoxic agent (e.g., cisplatin) can select for clones with globally heightened DDR capacity, which then resist multiple DNA‑damaging drugs and often show radioresistance as well.[^2][^8]


## Take‑home points

- There are recurrent **pathways** rather than a single universal mutation: defective p53 signaling, enhanced DDR, and increased anti‑apoptotic signaling are the main shared mechanisms behind cross resistance to chemotherapy and radiotherapy.[^3][^2][^1]
- Specific alterations frequently linked to cross resistance include *TP53* loss‑of‑function, high *RAD51* and other HR/NHEJ components, elevated *ERCC1*, overexpression of survivin/BCL‑2 family members, and regulatory changes such as loss of miR‑451 in lung adenocarcinoma.[^4][^9][^3][^1]
- The precise mutations vary by tumor type, and cross resistance is often an acquired, polygenic phenotype emerging under treatment pressure rather than being driven by a single mutation in isolation.[^2][^1]

<div align="center">⁂</div>

[^1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC5760393/

[^2]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11976711/

[^3]: https://www.oaepublish.com/articles/cdr.2020.89

[^4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC5352454/

[^5]: https://pubmed.ncbi.nlm.nih.gov/25201193/

[^6]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8368014/

[^7]: https://www.sciencedirect.com/science/article/abs/pii/S0753332217315020

[^8]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9259985/

[^9]: https://www.oncotarget.com/article/2176/text/

[^10]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8554658/

